LP-08 80mg + Normal saline + LP-08 20mg
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Cystitis
Conditions
Interstitial Cystitis
Trial Timeline
Jul 21, 2015 → Jun 14, 2018
NCT ID
NCT01393223About LP-08 80mg + Normal saline + LP-08 20mg
LP-08 80mg + Normal saline + LP-08 20mg is a phase 2 stage product being developed by Lipella Pharmaceuticals for Interstitial Cystitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01393223. Target conditions include Interstitial Cystitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01393223 | Phase 2 | Completed |
Competing Products
20 competing products in Interstitial Cystitis